Introduction {#s1}
============

The cytoskeleton controls cell morphology, polarity, division and movement but also organelle positioning, integrity and function. The Golgi apparatus is the central sorting and modification station of transmembrane and secretory proteins and has a perinuclear localization in interphase mammalian cells. The integrity and position of the Golgi complex are primarily governed by the microtubule network, with a smaller contribution of the actin cytoskeleton ([@bib2]). Microtubules are also implicated in the transport of vesicles from the Golgi and localized exocytosis. Furthermore, during directed migration of cells, microtubule remodeling positions the Golgi complex towards the leading edge to support polarized transport and is further required for the rapid turnover of focal adhesions (FAs) (reviewed in \[[@bib39]\]). The crosstalk between microtubules and the Golgi complex is coordinated by signaling factors including small GTPases such as Cdc42, Arf1, and Rho and their respective GEF and GAP proteins (reviewed in \[[@bib46]\]). For example, Arf1-mediated recruitment of the Cdc42-specific GAP ARHGAP21 (ARHGAP10) to Golgi membranes controls Cdc42 activity and microtubule-dependent positioning of the Golgi complex ([@bib17]; [@bib31]). Although Rho hyperactivation has been reported to lead to Golgi complex fragmentation ([@bib68]), the physiological relevance of this observation is not clear. ARHGEF2/GEF-H1 is a RhoGEF that is sequestered by microtubules and it is further regulated downstream of G-protein coupled receptor (GPCR) ligands ([@bib43], [@bib44]) and ERK signaling ([@bib26]; [@bib37]; [@bib57]; [@bib61]). GEF-H1 has been involved in exocytosis at the plasma membrane, FA turnover, response to mechanical forces, cell migration, and cell polarity (reviewed in \[[@bib52]\]), however, so far it has not been connected to vesicle fission at the Golgi complex.

The protein kinase D (PKD) family of serine/threonine kinases consisting of PKD1, PKD2, and PKD3 in mammals is enriched at the trans-Golgi network (TGN) where it coordinates the fission of vesicles destined for the plasma membrane ([@bib41]; [@bib42]). PKD is recruited to and activated at the TGN by the interaction with diacylglycerol (DAG) and Arf1 ([@bib5]; [@bib54]) and through direct phosphorylation by PKCη ([@bib15]). Because the level of DAG in TGN membranes controls the localization and activity of PKD, the pathways contributing to the local production of DAG are critical regulators of PKD-dependent transport carrier formation. For example, PKD phosphorylates and activates the lipid kinase PI4KIIIβ thereby increasing PtdIns(4)P levels at the TGN ([@bib29]). This, in turn, recruits the ceramide transfer protein CERT from the ER to the Golgi membranes, where CERT contributes to PKD activation by providing ceramide as a precursor for further DAG production ([@bib21]). Additionally, the family of PI-PLC enzymes, which generate DAG and inositol trisphosphate (IP~3~) through the hydrolysis of PtdIns(4,*5*)P~2~, are implicated in PKD activation downstream of Gβγ subunits ([@bib4]; [@bib16]). We previously reported that Golgi-localized PKD activity is enhanced by drug-induced microtubule depolymerization ([@bib20]) but how the microtubule network signaled to the TGN remained elusive. Here, we identify GEF-H1 to mediate PKD activation at the TGN upon nocodazole-induced release from microtubules. We provide evidence that GEF-H1 signals through RhoA and PLCε to control steady state and also G-Protein coupled receptor (GPCR)-induced activity of PKD at the TGN membranes. Most importantly, we show that at the TGN, PKD activated downstream of Rho stimulates the fission of Rab6-positive exocytic carriers delivering cargo to FAs. Consequently, through GEF-H1, the microtubule network controls anterograde trafficking from the TGN.

Results {#s2}
=======

RhoA activates PKD at the TGN {#s2-1}
-----------------------------

Nocodazole is a strong activator of PKD at TGN membranes ([@bib20]), suggesting that the microtubule network not only plays a structural role in maintaining Golgi complex position and shape but also signals to the Golgi complex to coordinate its function. Microtubule disruption was described to release the microtubule-associated RhoGEF GEF-H1 leading to the activation of the Rho GTPases RhoA and RhoB ([@bib3]; [@bib13]). We therefore first analyzed whether RhoA can activate PKD at the TGN. To do so, we employed a Golgi-localized PKD activity reporter previously developed in our lab, termed G-PKDrep, which specifically detects PKD activity at the TGN ([@bib20]). When cells expressed constitutive active RhoA Q63L, the reporter phosphorylation and thus PKD activity significantly increased up to twofold (0.2284 (median control)) versus 0.4826 (median RhoA Q63L)) whereas expression of wild type (wt) RhoA had no effect compared to the control cells ([Figure 1A and B](#fig1){ref-type="fig"}). As reported previously, expression of RhoA Q63L resulted in Golgi fragmentation ([@bib68]) and stress fiber formation ([Figure 1A and C](#fig1){ref-type="fig"}). In support of a local role for RhoA in the activation of PKD we could detect GFP-tagged RhoA Q63L at TGN membranes indicated by the co-localization with the trans-Golgi marker p230 ([Figure 1C](#fig1){ref-type="fig"}). Similarly, active RhoB Q63L localized to the TGN and activated PKD at this site ([Figure 1---figure supplement 1A--C](#fig1s1){ref-type="fig"}). We further quantified the co-localization of RhoA and RhoB with Rab6, a TGN-localized Rab GTPase involved in the fission of transport carriers ([@bib48]), using the Manders' coefficient. Indeed, the co-localization of constitutive active RhoA and RhoB with Rab6 was significantly higher when compared to their wild-type counterparts, further supporting a role for active Rho at TGN membranes ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}).

![RhoA activates PKD at the TGN.\
HeLa cells were transfected with G-PKDrep plus control vector, or a plasmid encoding HA-tagged RhoA wt or RhoA Q63L. One day after transfection cells were fixed and stained for G-PKDrep phosphorylation (pSer294) and F-actin (Alexa633-labelled phalloidin). Images were quantified by ratiometric calculation of GFP and Alexa546-labelled pSer294 signal. (**A**) Shown are representative confocal images, scale bar 10 µm. (**B**) The box plot shows the results of three independent experiments. Center lines show the medians; box limits indicate the 25th and 75th percentiles as determined by GraphPad Prism 7 software; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots. n = 72 sample points each. The significance of differences was analyzed by a one-way ANOVA (Kruskal-Wallis test) followed by a Dunn's multiple comparison test. \*\*\*\*p\<0.0001 (control vs. RhoA Q63L). (**C**) HeLa cells were transfected with a plasmid encoding GFP-tagged RhoA Q63L, fixed 24 hr later, and stained for the trans Golgi protein p230 (red). Shown is a confocal image, scale bar 10 µm. Yellow regions indicate co-localization. \* indicates cells with a compact Golgi complex, \# indicates cells with a fragmented Golgi complex.](elife-35907-fig1){#fig1}

Rho-mediated PKD activation at the TGN requires GEF-H1 {#s2-2}
------------------------------------------------------

GEF-H1 directly binds to microtubules and, when bound, is inactive ([@bib40]). With increasing microtubule depolymerization, GEF-H1 is released and free to activate Rho ([@bib3]; [@bib13]). To examine whether GEF-H1 is responsible for mediating PKD activation downstream of RhoA, we knocked down GEF-H1 using two independent siRNAs. Indeed, in GEF-H1-depleted cells nocodazole-induced PKD activation was strongly reduced ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). GEF-H1 can be activated downstream of ERK signaling ([@bib22]; [@bib26]; [@bib37]; [@bib61]). In HEK293T cells, nocodazole treatment strongly induced the MAPK pathway. Simultaneous MEK1/2 inhibition, however, did not impair phosphorylation of PKD ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}) proving that GEF-H1-mediated PKD activation is independent of ERK. In agreement with our GEF-H1 depletion results, expression of GEF-H1 wt and GEF-H1 C53R, a mutant that does not bind microtubules and is thus constitutively active ([@bib40]), was sufficient to activate PKD ([Figure 2B](#fig2){ref-type="fig"}). Of note, GEF-H1 C53R induced PKD activation was stronger compared to GEF-H1 wt. Analogous to the expression of active RhoA, expression of GEF-H1 C53R induced fragmentation of the Golgi complex whereas in cells expressing GEF-H1 wt the Golgi complex remained compact ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}). To corroborate the GEF-H1-induced PKD activation at the TGN we again used G-PKDrep. In cells expressing GEF-H1 wt, the reporter phosphorylation was significantly enhanced compared to the control cells without ectopic GEF-H1 expression ([Figure 2C](#fig2){ref-type="fig"}). In agreement with the quantitative Western Blot results ([Figure 2B](#fig2){ref-type="fig"}), reporter phosphorylation was stronger in the case of GEF-H1 C53R expression ([Figure 2C](#fig2){ref-type="fig"}).

![Nocodazole-mediated PKD activation at the TGN requires GEF-H1.\
(**A**) HEK293T cells were transfected with spGEF-H1, spNT was used as a control. Three days after transfection cells were stimulated with nocodazole for 60 min, lysed and analyzed for PKD activity (pPKD (Ser744/748) and expression of PKD1, 2, and 3. Detection of alpha tubulin served as a loading control. Successful depletion of GEF-H1 was verified by detection with a GEF-H1 specific antibody. Shown is a representative Western blot. The integrated density of the pPKD and PKD1-3 signal was measured, corrected for background signals and the ratio (pPKD/PKD) calculated. Data were normalized to the control (spNT -nocodazole), which was set to 100. The graphs show the mean ± SEM of three independent experiments. The significance of differences was analyzed by a Ratio paired t-test (two-tailed). \*\*\*p=0.0007 (ratio pPKD Ser744/748/PKD1) and p=0.0002 (ratio pPKD Ser744/748/PKD2), \*\*p=0.0014 (ratio pPKD Ser744/748/PKD3). (**B**) FlpIn T-Rex 293 EGFP-GEF-H1 wt or FlpIn T-REx 293 EGFP-GEF-H1 C53R cells were left untreated (-) or treated with doxycyline for 18 hr (+). Cells were lysed and analysed for PKD activity, PKD1-3 expression and endogenous as well as ectopic GEF-H1 expression. Detection of alpha tubulin served as loading control. Shown is a representative Western blot. Quantification of Western blot data was done as described in [Figure 2A](#fig2){ref-type="fig"}. Data were normalized to the control (GEF-H1 wt untreated), which was set to 100. The graphs show the mean ± SEM of three independent experiments. The significance of differences was analyzed by a Ratio paired t-test (two-tailed). \*p=0.0365 (ratio pPKD Ser744/748/PKD1) and \*\*p=0.0023 (ratio pPKD Ser744/748/PKD2). (**C**) FlpIn T-Rex HeLa EGFP-GEF-H1 wt or EGFP-GEF-H1 C53R cells were transfected with a Cherry-tagged G-PKDrep. One day after transfection cells expression of GEF-H1-GFP was induced by doxycyline. One day later, cells were fixed and stained for G-PKDrep phosphorylation (pSer294). Images were quantified by ratiometric calculation of Cherry and Alexa633-labelled pSer294 signal. Cells without doxycycline treatment were used as control. The box plot shows the results of three independent experiments. Center lines show the medians; box limits indicate the 25th and 75th percentiles as determined by GraphPad Prism 7 software; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots. n = 89, 56, 23 sample points. The significance of differences was analyzed by a one-way ANOVA (Kruskal-Wallis test) followed by a Dunns multiple comparison test. \*\*\*\*p\<0.0001 (control vs GEF-H1 wt or GEF-H1 C53R). (**D**) HeLa cells were transfected with the indicated siRNAs. Two days later, cells were transfected with the RhoA Biosensor along with mRuby-Golgi-7 (ratio 6:1) and, after 24 hr, stimulated with nocodazole and imaged. Left panel, representative images taken at 0 and 30 min of stimulation are shown; scale bar 10 µm. Right panel, the graph shows the mean ± SEM of at least 40 cells imaged in two independent experiments. The arrow indicates the time point of nocodazole stimulation. Successful depletion of GEF-H1 was verified by Western Blot analysis. Detection of alpha tubulin served as a loading control.](elife-35907-fig2){#fig2}

We next sought to prove that the RhoA pool activated by GEF-H1 is present on TGN membranes by tracking RhoA activity in living cells using an unimolecular RhoA activity FRET biosensor ([@bib53]). This RhoA biosensor was described to co-localize with Golgi membrane markers ([@bib53]). In HeLa cells the RhoA biosensor also displayed a partial co-localization with a co-expressed Golgi marker protein (mRuby-Golgi-7) ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). We stimulated control and GEF-H1 depleted cells with nocodazole and measured RhoA activity over time by ratiometric FRET imaging (see [Figure 2D](#fig2){ref-type="fig"} for FRET images at 0 and 30 min). As previously reported ([@bib56]), nocodazole stimulation led to a GEF-H1-dependent increase in RhoA activity in the cell periphery (see images in [Figure 2D](#fig2){ref-type="fig"}). At the Golgi, RhoA activity increased steadily and reached a plateau 10 min after nocodazole treatment in control cells. In GEF-H1 depleted cells, however, no increase in RhoA activity at the cell periphery and the Golgi was observed (see images and graph in [Figure 2D](#fig2){ref-type="fig"}). Our data thus provide strong support for GEF-H1 promoting increased Rho activity in the cell periphery and at the Golgi membranes.

The Rho effector PLCε is required for PKD activation at the TGN {#s2-3}
---------------------------------------------------------------

Rho GTPases engage various downstream effector proteins, some of which were previously linked to Golgi complex function. For example, mDia1 was reported to mediate RhoA-induced Golgi fragmentation ([@bib68]), however, in our experimental system, depletion of mDia1 did not affect RhoA-mediated PKD activation at Golgi membranes ([Figure 3A, B and C](#fig3){ref-type="fig"}). The Rho effector kinases ROCK1 and 2 were shown to mediate cell contractility downstream of nocodazole-induced Rho activation ([@bib13]) and expression of constitutive active ROCK1 induced Golgi fragmentation ([@bib50]), but neither the single, nor the combined depletion of ROCK1 and ROCK2 affected Golgi-associated PKD activity ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Pharmacological ROCK inhibition by H1152 also failed to block RhoA Q63L-induced PKD activation ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}).

![The Rho effector PLCε is required for GEF-H1 mediated PKD activation at the TGN.\
(**A**) HeLa cells were transfected with spRNAs as indicated, spNT was used as a control. Two days after transfection cells were transfected with G-PKDrep and RhoA Q63L and, after 24 hr, fixed, stained and analyzed as described in [Figure 1A](#fig1){ref-type="fig"}. Shown are representative confocal images, scale bar 10 µm. (**B**) The box plot shows the results of three independent experiments. Center lines show the medians; box limits indicate the 25th and 75th percentiles as determined by GraphPad Prism 7 software; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots. n = 90 sample points each. The significance of differences was analyzed by a one-way ANOVA followed by a Dunns multiple comparison test. \*\*\*p\<0.0001. (**C**) Left panel, silencing efficiency of mDia1 was analyzed in lysates by immunoblotting using a mDia1-specific antibody. Equal loading was verified by detection of alpha tubulin. Right panel, successful depletion of PLCε was verified by RT-qPCR. Relative expression was calculated by normalization to GAPDH using the ΔCq method. Shown is the mean ± SEM of two independent experiments. (**D**) Left panel, HEK293T cells were transfected with the spPLCε, spNT was used as a control. Three days post transfection cells were left untreated or stimulated with nocodazole for 60 min. Detection of active PKD and expression of PKD1-3 was performed in cell lysates using specific antibodies. Equal loading was verified by detection of alpha tubulin. Shown is a representative Western blot. Right panel, quantification of Western blot data was done as described in [Figure 2A](#fig2){ref-type="fig"}. Data were normalized to the control (untreated spNT cells), which was set to 100. The graphs show the mean ± SEM of three independent experiments. The significance of differences was analyzed by a Ratio paired t-test (two-tailed). \*\*\*p=0.0007 (ratio pPKD Ser744/748/PKD1), \*p=0.0334 (ratio pPKD Ser744/748/PKD2), and \*\*p=0.0026 (ratio pPKD Ser744/748/PKD3). Successful depletion of PLCε was verified by RT-qPCR. Relative expression was calculated by normalization to Actin using the ΔCq method. Shown is the mean ± SEM of three independent experiments. The significance of differences was analyzed by a Ratio paired t-test (two-tailed). \*p=0.0157 (**E**) Left panel, FlpIn T-REx 293 EGFP-GEF-H1 C53R cells were transfected with spPLCε, spNT was used as a control. Two days later, GFP-GEF-H1 C53R expression was induced by doxycycline treatment. After one day, cells were lysed and analysed for PKD activity, PKD1-3 expression and endogenous as well as ectopic GEF-H1 expression. Detection of alpha tubulin served as a loading control. Shown is a representative Western blot. Right panel, quantification of Western blot data was done as described in [Figure 2A](#fig2){ref-type="fig"}. Data were normalized to the control (spNT cells without doxycycline), which was set to 100. The graphs show the mean ± SEM of three independent experiments. The significance of differences was analyzed by a Ratio paired t-test (two-tailed). \*p=0.0266 (ratio pPKD Ser744/748/PKD1), p=0.0106 (ratio pPKD Ser744/748/PKD2), and p=0.0152 (ratio pPKD SerS744/748/PKD3). Successful depletion of PLCε was verified by RT-qPCR. Relative expression was calculated by normalization to Actin using the ΔCq method. Shown is the mean ± SEM of three independent experiments.](elife-35907-fig3){#fig3}

PLCε is a Rho effector protein found to localize to the Golgi complex in cardiac myocytes ([@bib67]) where it hydrolyzes PtdIns(4)P resulting in the production of DAG. We thus investigated whether PLCε was involved in PKD activation. Indeed, depletion of PLCε using independent siRNAs significantly reduced RhoA-mediated PKD activation at the TGN ([Figures 3A and B and C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Furthermore, in cells depleted of PLCε, nocodazole treatment no longer resulted in the PKD activation seen in the control cells ([Figure 3D](#fig3){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), confirming that PLCε is downstream of RhoA in PKD activation at Golgi membranes. To address whether the GEF-H1 dependent PKD activation requires PLCε, we expressed GEF-H1 C53R in cells depleted of PLCε and monitored PKD activity by Western blot analysis. In control cells, GEF-H1 C53R potently activated PKD whereas the loss of PLCε diminished the GEF-H1 C53R-mediated PKD activation ([Figure 3E](#fig3){ref-type="fig"}).

Because PLCε is responsible for the production of DAG, we reasoned that PLCε should also be involved in the maintenance of basal PKD activity at Golgi membranes. To test this assumption, we quantitatively analyzed the subcellular localization of a kinase-dead PKD1-GFP fusion protein commonly used as a sensor for DAG ([@bib5]) by measuring its fluorescence intensity at the Golgi complex and in the cytoplasm. As shown in [Figure 4A](#fig4){ref-type="fig"} (top), PKD1kd was enriched at Golgi membranes and a smaller portion was also present in the cytosol. Quantification revealed that in cells depleted of PLCε, the amount of PKD1kd at Golgi membranes was reduced compared to control cells ([Figure 4A](#fig4){ref-type="fig"}, bottom). This suggests that the loss of PLCε decreases DAG at and thus PKD localization to Golgi membranes. Consequently, basal PKD activity should be dependent on PLCε as well. Indeed, quantitative measurement of G-PKDrep phosphorylation revealed that PLCε depletion led to a modest but significant reduction in PKD activity at TGN membranes compared to control cells ([Figure 4B and C](#fig4){ref-type="fig"}). Thus, PLCε is involved in the regulation of both, basal PKD activity and nocodazole-induced PKD activation at Golgi membranes.

![PLCε is required for basal and trypsin-induced PKD activity at the TGN.\
(**A**) Top panel, HeLa cells were transfected with spPLCε, spNT was used as a control. Two days later, cells were transfected with a plasmid encoding PKD1kd-GFP. After 24 hr, cells were fixed and stained for p230. Representative confocal images are shown; scale bar 10 µm. CellProfiler images show the masks defining the Golgi complex (blue) and the cytosol (yellow) merged with the PKD1kd-GFP image (shown in greyscale). Bottom panel, the fluorescence intensities of the GFP signal were measured under both masks and the Golgi/Cytosol ratio was calculated for each cell. The graph shows the mean ± SEM of at least 150 cells analysed. (**B**) HeLa cells were transfected with siRNAs as described in E. Two days later, cells were transfected with G-PKDrep. Visualization and analysis of G-PKDrep phosphorylation was performed as described in [Figure 1A](#fig1){ref-type="fig"}. Shown are representative confocal images, scale bar 10 µm. (**C**) Left panel, the box plot shows the results of three independent experiments. Center lines show the medians; box limits indicate the 25th and 75th percentiles as determined by GraphPad Prism 7 software; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots. n = 114, 104 sample points. The significance of differences was analyzed by a two-tailed t-test (Mann-Whitney test), \*p\<0.05. Right panel, successful depletion of PLCε was verified by RT-qPCR. Relative expression was calculated by normalization to GAPDH using the ΔCq method. Shown is the mean ± SEM of two independent experiments. (**D**) HEK293T cells were left untreated or stimulated with trypsin. Cells were lysed and detection of active PKD (pPKD Ser744/748) and expression of PKD1-3 was performed using specific antibodies. Equal loading was verified by detection of alpha tubulin. (**E, F**) HeLa cells were transfected with spRNAs as indicated, spNT was used as a control. Two days after transfection cells were transfected with G-PKDrep. 24 hr later, cells were left untreated or stimulated with trypsin, fixed, stained and analyzed as described in [Figure 1A](#fig1){ref-type="fig"}. (**E**) Shown are representative confocal images of the spNT control, scale bar 10 µm. (**F**) The scatter dot blot shows the result of three independent experiments, line indicates the mean. Each dot represents one experiment with at least 30 cells analysed. The significance of differences was analyzed by a one-way ANOVA (Friedman test) followed by a Dunn's multiple comparison test. \*p=0.0306 (spNT -- trypsin vs. spNT + trypsin). All other comparisons were not significant. Successful depletion of the proteins was verified by Western blot or RT-qPCR (data not shown).](elife-35907-fig4){#fig4}

GPCRs, in particular the family of protease activated receptors (PAR), which are activated by trypsin, thrombin and factor Xa, as well as LPA responsive receptors trigger the activation of GEF-H1, independently of microtubule depolymerization ([@bib44]). Notably, in astrocytes, thrombin activates PKD downstream of PLCε ([@bib19]). Moreover, activation of PAR2 through trypsin induced PKD activity at the Golgi complex ([@bib35]), raising the question whether PAR signaling has a physiological function in connecting the plasma membrane with the Golgi complex through GEF-H1. Indeed, short trypsin stimulation strongly activated PKD as shown by activation loop phosphorylation of the kinase ([Figure 4D](#fig4){ref-type="fig"}). To address whether PARs are upstream of GEF-H1 and PLCε we stimulated HeLa cells expressing G-PKDrep with trypsin and measured PKD activation at the Golgi by ratiometric imaging in control and GEF-H1- and PLCε-depleted cells. Knockdown of PKD2 and PKD3 served as a control. Our results clearly show that trypsin treatment significantly activated PKD at the Golgi complex in control cells ([Figure 4E and F](#fig4){ref-type="fig"}). However, in cells depleted of GEF-H1, PLCε or PKD2/3, trypsin-mediated PKD activation was diminished compared to control cells ([Figure 4F](#fig4){ref-type="fig"}). Furthermore, short thrombin stimulation also led to strong phosphorylation of G-PKDrep which was fully blocked by treatment with the pan-PKD inhibitor CRT0066101 ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}) placing PARs upstream of a GEF-H1-PKD signaling pathway.

The RhoGAP DLC3 counterbalances GEF-H1-mediated PKD activation at the TGN {#s2-4}
-------------------------------------------------------------------------

Rho GTPase activation requires the spatially coordinated action of specific GEFs and GAPs. Recently, we identified Deleted in Liver Cancer 3 (DLC3), a RhoGAP protein with specificity for RhoA ([@bib33]) to control RhoA-GTP levels at Golgi membranes. Depletion of DLC3 in HeLa cells significantly increased basal RhoA activity at this compartment resulting in fragmentation of the Golgi complex ([@bib9]). To address whether DLC3 could be a counterplayer of GEF-H1 in PKD activation at the Golgi complex, we depleted DLC3 in HeLa cells and analyzed PKD activity at the TGN using the G-PKDrep phosphorylation as a read out ([Figure 5A](#fig5){ref-type="fig"}). Importantly, we detected a significant increase in PKD activity when DLC3 was absent ([Figure 5B](#fig5){ref-type="fig"}). To corroborate this finding, we performed a set of rescue experiments. Along with DLC3, we depleted either the Rho effector PLCε or the RhoGEF GEF-H1. If DLC3 and GEF-H1 control the same RhoA pool, depletion of GEF-H1 or the Rho effector PLCε should rescue the PKD activation induced by DLC3 depletion. Indeed, when both proteins, DLC3 plus GEF-H1 or DLC3 plus PLCε were depleted, the significant increase in PKD activity as observed in DLC3-depleted cells was fully rescued ([Figure 5C and D](#fig5){ref-type="fig"}). Our results thus indicate that GEF-H1, Rho and PLCε are in a linear signaling pathway that links the microtubule network with PKD activity at the TGN and is counterbalanced by DLC3.

![Loss of the RhoGAP DLC3 promotes PKD activation at the TGN.\
(**A**) HeLa cells were transfected with spRNAs as indicated. Two days after transfection cells were transfected with G-PKDrep and, after 24 hr, fixed, stained and analyzed by ratiometric measurement as described in [Figure 1A](#fig1){ref-type="fig"}. Representative confocal images are shown, scale bar 10 µm. (**B**) Top panel, the box plot shows the results of three independent experiments. Center lines show the medians; box limits indicate the 25th and 75th percentiles as determined by GraphPad Prism 7 software; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots. n = 90 sample points each. The significance of differences was analyzed by a two-tailed t-test (Mann-Whitney test). \*\*\*\*p\<0.0001. Bottom panel, silencing efficiency of DLC3 was analyzed in lysates by immunoblotting using a DLC3-specific antibody. Equal loading was verified by detection of alpha tubulin. (**C**) Cells were transfected with spRNAs as indicated. Two days after transfection cells were transfected with G-PKDrep and, after 24 hr, fixed, stained and analyzed by ratiometric imaging as described in 1A. Representative confocal images are shown, scale bar 10 µm. (**D**) The box plot shows the results of three independent experiments. Center lines show the medians; box limits indicate the 25th and 75th percentiles as determined by GraphPad Prism 7 software; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots. n = 83, 73, 73, 75, 73, 75 sample points. The significance of differences was calculated by a one-way ANOVA (Kruskal-Wallis test) followed by a Dunn's multiple comparison test. \*\*\*\*p\<0.0001, **\***p=0.0393. ns, not significant. Right panel, silencing efficiency of GEF-H1 and DLC3 were verified in lysates by immunoblotting using specific antibodies. Detection of alpha tubulin served as a loading control.](elife-35907-fig5){#fig5}

GEF-H1, PLCε and PKD are required for localized delivery of Rab6 to FAs {#s2-5}
-----------------------------------------------------------------------

At the TGN, PKD controls the fission of vesicles containing basolateral cargo destined for the plasma membrane. The carriers generated by PKD were named CARTS (CARriers of the TGN to the cell Surface) and are characterized by the presence of the small GTPases Rab6a and Rab8a ([@bib62]). A previous report showed that nocodazole treatment or expression of active RhoA recruits Rab8 to Golgi membranes ([@bib27]), prompting us to investigate whether this is regulated by PKD. We thus stained HeLa cells, which were transiently transfected with a plasmid encoding wt PKD1-GFP, for Rab8 or Rab6 and the trans-Golgi marker p230. In HeLa cells expressing PKD1-GFP, Rab8 co-localized with p230 and PKD1-GFP at trans-Golgi membranes whereas in cells without ectopic PKD1-GFP expression Rab8 was found on tubular and/or vesicular structures, which did not show an overlap with the trans-Golgi marker p230 ([Figure 6A](#fig6){ref-type="fig"}, top panel, histograms). Rab6 was strongly enriched at the TGN, indicated by the co-localization with p230 and PKD1-GFP, however, the localization of Rab6 at trans-Golgi membranes was independent of PKD1-GFP expression ([Figure 6A](#fig6){ref-type="fig"}, bottom panel, and histogram). Our observations were confirmed by a quantitative object-based co-localization analysis using CellProfiler software ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), which clearly showed that ectopic expression of PKD1-GFP or PKD2-GFP significantly increased the Golgi localization of Rab8, whereas in GFP vector transfected cells Rab8 localization remained unchanged ([Figure 6B](#fig6){ref-type="fig"}). Our results thus position PKD upstream of Rab8 recruitment to Golgi membranes.

![PKD recruits Rab8 to the TGN and co-localizes with Rab6.\
(**A**) HeLa cells were transfected with a plasmid encoding wt PKD1-GFP. One day after transfection, cells were fixed and stained for Rab8 (top panel) or Rab6 (bottom panel) plus p230 and analyzed by confocal microscopy. Scale bar 10 µm. Right panel, in the histogram (profile scan) the fluorescence intensities of the three signals along the white line are depicted. (**B**) HeLa cells were transfected with an empty GFP vector, PKD1-GFP or PKD2-GFP constructs and stained for Rab6 or Rab8 and the TGN marker protein p230. Co-localization analysis of Rab8 or Rab6 with the TGN in GFP positive and GFP negative cells was performed using Cell Profiler software as described in the material and methods section. The graph shows the mean ± SEM of three independent experiments. Significance of differences was analyzed by a two-way RM ANOVA followed by a Bonferroni's multiple comparison test. \*\*\*p=0.0004, \*\*p=0.001.](elife-35907-fig6){#fig6}

Recently, Rab6 was connected to a FA-directed exocytosis pathway. The docking and fusion of Rab6 vesicles within the plasma membrane occurred preferentially near FAs ([@bib59]). Moreover, Rab6-positive vesicles exit the Golgi at fission hotspots ([@bib47]). We thus speculated that the Rho-PKD signaling pathway might control the exit of Rab6 vesicles from the TGN and thus the localized delivery of these vesicles to FAs. To address this we performed TIRF analysis of HeLa cells expressing GFP-tagged Rab6A and DsRed2-tagged paxillin. We monitored the arrival of Rab6A vesicles in the vicinity of DsRed2-paxillin in cells transfected with a control siRNA (spNT), and in cells depleted of GEF-H1, PLCε, and PKD2 together with PKD3, respectively. As previously reported, in control cells Rab6A vesicles arrived at membrane domains proximal to FAs, stalled for a short period of time and then rapidly disappeared. Loss of GEF-H1, PLCε, or PKD2/PKD3, however, significantly decreased the number of Rab6A-positive vesicles arriving at FAs, with cells depleted of the two PKD isoforms showing the strongest effect ([Figure 7A and C](#fig7){ref-type="fig"}, [Figure 7---Video 1](#fig7video1){ref-type="video"}). Of note, the total number of FAs per cell was not affected by the loss of any of the proteins ([Figure 7B](#fig7){ref-type="fig"}). Interestingly, the depletion of GEF-H1 resulted in an upregulation of PLCε mRNA levels supporting the molecular connection of the two proteins ([Figure 7D](#fig7){ref-type="fig"}). Whether protein levels are also enhanced remains unknown because we could not detect PLCε by Western blot analysis. Notably, depletion of DLC3 slightly decreased the number of vesicles arriving at FAs compared to control cells although PKD activity was increased under these conditions (data not shown). However, as DLC3 depletion induced the fragmentation of the Golgi complex (see [Figure 5A](#fig5){ref-type="fig"} and \[[@bib9]\]) it is likely that the polarized delivery of Rab6 vesicles to FAs is negatively affected. This also supports the hypothesis that Rho levels at the Golgi complex have to be tightly regulated to ensure proper vesicular trafficking. To connect GPCR signaling with the FA-directed exocytotic pathway, we stimulated control and PKD2/3 depleted HeLa cells with thrombin and quantified the Rab6 vesicles arriving at paxillin-positive FA over time by TIRF kymography. Our data clearly show that thrombin stimulation significantly increased the number of Rab6 vesicles arriving at FAs in control but not in PKD2/3 depleted cells ([Figure 7E](#fig7){ref-type="fig"}). We thus demonstrate that activation of PARs induces PKD-dependent localized exocytosis. We also followed the dynamic movement of CLIP170, a microtubule plus end tip, in HeLa cells expressing DsRed2-paxillin. As shown by the kymographs, in PLCε-depleted cells microtubule plus ends contacted FAs as efficiently as in control cells, proving that the loss of the Rho effector PLCε does not interfere with the microtubule-FA interaction per se ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). We thus conclude that perturbations of the GEF-H1/Rho/PLCε/PKD signaling axis affect Rab6 vesicles already at the level of the TGN.

![GEF-H1, PLCε and PKD are required for localized delivery of Rab6 to FAs.\
(**A, B, C, D, E**) Cells were transfected with spRNAs as indicated. Two days later cells were transfected with plasmids encoding GFP-tagged Rab6 and DsRed2-tagged paxillin. After 24 hr cells were analyzed at a TIRF-equipped Spinning disc microscope. The amount of Rab6-positive vesicles arriving at FAs was assessed within a two minute time interval. (**A**) The box plot shows the results of three independent experiments. Center lines show the medians; box limits indicate the 25th and 75th percentiles as determined by GraphPad Prism 7 software; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots. n = 26, 26, 26, 20 sample points. The significance of differences was assessed by a one-way ANOVA (Kruskal Wallis test) followed by a Dunn's multiple comparison test. \*\*\*\*p\<0.0001, \*\*\*p=0.002. (**B**) Top panel, number of FAs per cell. Bottom panel, number of vesicles arriving at FAs within two minutes. Center lines show the medians; box limits indicate the 25th and 75th percentiles as determined by GraphPad Prism 7 software; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots. n = 26, 26, 26, 20 sample points. (**C**) Representative TIRF images. Red dots indicate Rab6-positive vesicles arriving at FAs within the two minute time interval. Scale bar 10 µm. (**D**) Left panel, silencing efficiency of GEF-H1, PKD2 and PKD3 was analyzed in lysates by immunoblotting using specific antibodies. Equal loading was verified by detection of alpha tubulin. Right panel, successful depletion of PLCε was verified by RT-qPCR. Relative expression was calculated by normalization to actin using the ΔCq method. (**E**) Cells were imaged 5 min prior to stimulation with thrombin or PBS (as a control). After addition of the reagent, imaging was continued for 30 min. Left panel: The box plot shows the result of three independent experiments. The vesicles arriving at FAs per minute before and after stimulation were calculated and presented as ratio '*number of vesicles at FA after/before stimulation'*. Center lines show the medians; box limits indicate the 25th and 75th percentiles as determined by GraphPad Prism 7 software; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots. n = 7, 12, 10 sample points (cells analyzed). The significance of differences was assessed by a one-way ANOVA (Kruskal Wallis test) followed by a Dunn's multiple comparison test. \*\*p\<0.01, ns not significant. Right panel: Representative TIRF kymographs of spNT and spPKD2/3 cells. Arrows indicate vesicles arriving at FAs.](elife-35907-fig7){#fig7}

To provide further proof that the GEF-H1/Rho/PLCε signaling axis regulates PKD-controlled vesicle biogenesis at the TGN we employed the retention using selective hooks (RUSH) assay ([@bib8]). In this system, secretory cargo is retained in the ER through streptavidin-based retention and released to the secretory pathway upon biotin addition. Since TNFα was shown to be transported in Rab6 vesicles from the TGN to the plasma membrane (\[[@bib45]\] and [Figure 8A](#fig8){ref-type="fig"}) and is exocytosed at FAs (personal correspondence F. Perez (Institute Curie, Paris) November, 2017), we studied whether TNFα secretion is controlled by the GEF-H1-dependent Rho signaling network. To do so, we expressed Str-KDEL-TNFα-SBP-mCherry in HeLa cells and analyzed the post-Golgi transport in fixed samples ([Figure 8B and C](#fig8){ref-type="fig"}) and by live cell imaging ([Figure 8D](#fig8){ref-type="fig"}). While TNFα-SBP-mCherry clearly left the Golgi and reached the plasma membrane after biotin addition in control cells, GEF-H1, PLCε, and PKD2/3 knockdown caused a substantial block in transport of TNFα-SBP-mCherry from the TGN to the plasma membrane ([Figure 8C and D](#fig8){ref-type="fig"}, [Figure 8---Video 1](#fig8video1){ref-type="video"}). Notably, we could not observe any changes in the trafficking of TNFα between the ER and the Golgi complex (data not shown). These data clearly show that Rho-controlled PKD activation at the TGN induces the fission of Rab6-vesicles containing cargo for targeted exocytosis at FAs.

![The Rho signaling pathway controls vesicle fission and cargo transport at the level of the TGN.\
(**A**) HeLa cells were transfected with a construct encoding Str-KDEL-TNFα-SBP-mCherry together with Rab6-GFP. 24 hr later, biotin was added for 35 min followed by fixation. Cells were stained for p230 and analyzed by confocal microscopy. Shown is a maximum intensity projection, scale bar 10 µm. (**B, C, D**) HeLa cells were transfected with spRNAs as indicated, spNT was used as a control. (**B, C**) Two days later cells were transfected with plasmids encoding Str-KDEL-TNFα-SBP-mCherry and Rab6-GFP and, after 24 hr, biotin was added and cells were subjected to the RUSH assay as described in the material and methods section. After fixation, cells were stained for p230. Shown are representative confocal images, scale bar 10 µm. (**C**) Left panel, the scatter dot blot shows the result of three independent experiments, line indicates the mean. Each dot represents one experiment with at least 190 cells analysed. The significance of differences was analyzed by a one-way ANOVA followed by a Holm-Sidak's multiple comparison test, \*\*p=0.0065. All other comparisons were not significant. Right panel, successful depletion of the proteins was verified by RT-qPCR. Relative expression was calculated by normalization to actin using the ΔCq method. The graphs represent the mean ± SEM of three independent experiments. (**D**) HeLa cells were transfected with a plasmid encoding Str-KDEL-TNFα-SBP-mCherry and release from the ER was induced by biotin addition 24 hr later. The graph shows integrated fluorescence intensity in the Golgi region at each time point, corrected for background and normalized to the maximum value. Curves depict the measurement of at least 22 cells of a representative experiment. Error bars, SEM.](elife-35907-fig8){#fig8}

Taken together, our studies uncover a microtubule-sensitive Rho signaling network that controls Golgi complex secretory function ([Figure 9](#fig9){ref-type="fig"}). We propose that extracellular cues signal through this network to the Golgi complex to coordinate the formation of membrane carriers that transport secreted factors to FAs.

![Schematic illustration of the Rho signaling pathway at the TGN.\
GPCR signaling activates GEF-H1 by releasing it from microtubules. GEF-H1 in turn promotes an increase in cellular RhoA activity. At the TGN, active RhoA binds to its effector PLCε, which hydrolyzes PtdIns(4)P to generate DAG and IP2. DAG recruits and activates nPKCs and PKD, which gets further activated by nPKC-mediated phosphorylation. The activation of PKD by RhoA is counterbalanced by the RhoGAP DLC3. Active PKD recruits Rab8 to TGN membranes and induces the fission of Rab6-positive vesicles containing cargo such as TNFα destined for FA-targeted transport along microtubules.](elife-35907-fig9){#fig9}

Discussion {#s3}
==========

Here we identify a Rho-dependent signaling network connecting microtubules with PKD-dependent vesicle fission at the TGN. Specifically, we demonstrate that GEF-H1, when released from microtubules, enhances cellular RhoA activity, which in turn promotes PKD activation at the TGN through the Rho effector PLCε, ultimately leading to the fission of Rab6-positive vesicles that move towards FAs.

The RhoGEF GEF-H1 is crucial for the coupling of microtubule dynamics to Rho GTPase activation in several biological situations such as cell polarization and motility and cell cycle regulation (reviewed in \[[@bib7]\]). GEF-H1 is a well-known activator of RhoA but it can also act as a GEF for RhoB ([@bib3]; [@bib60]). Release and activation of GEF-H1 can be achieved by disrupting polymerized microtubules through pharmacological compounds or, independent of microtubule disassembly, through GPCR signaling ([@bib44]). Here we show that both modes of GEF-H1 activation, nocodazole treatment and trypsin or thrombin-induced GPCR stimulation, initiate a Rho signaling cascade leading to PKD activation and the fission of vesicles at TGN membranes. Previous studies have demonstrated a role for GEF-H1 in vesicular trafficking: Bokoch and co-workers showed that GEF-H1 interacts with the exocyst component Sec5 leading to local RhoA activation thereby promoting exocyst assembly and exocytosis ([@bib51]). Additionally, the targeted trafficking of c-Src--associated endosomes to the cell periphery was reported to depend on the GEF-H1-mediated activation of endosomal RhoB ([@bib3]). It is thus evident that the subcellular localization of the microtubule-regulated GEF-H1 determines the spatio-temporal activation of specific Rho pools and Rho isoforms. In general, the spatial distribution of GEF-H1 is regulated by protein interactions. For example, the junctional adaptor cingulin recruits GEF-H1 to tight junctions thereby inactivating its GEF activity and inhibiting Rho signaling ([@bib1]). By contrast, the interaction of GEF-H1 with Sec5 promotes RhoA activation at the exocyst complex ([@bib51]) and is important for GEF-H1 localization to FAs ([@bib63]). Recently, plasma membrane associated active RhoA was demonstrated to recruit GEF-H1 thereby promoting a self-amplification loop. At the same time, active RhoA was also shown to inhibit itself by the local recruitment of the actomyosin-associated RhoGAP Myo9b ([@bib23]). A similar autoregulatory loop involving GEF-H1, Rho and the RhoGAP DLC3 might drive the self-limiting fission of exocytic vesicles at the TGN. Although previous reports demonstrated GEF-H1 localization to Golgi membranes ([@bib6]; [@bib10]), we were not able to detect endogenous or ectopically expressed GEF-H1 at the TGN. The question of whether GEF-H1 activates Rho directly at the TGN or whether Rho is activated elsewhere and then recruited to Golgi membranes thus remains open.

Hyperactivation of Rho has been linked to Golgi complex fragmentation ([@bib14]; [@bib68]). Zilberman and colleagues identified the Rho effector mDia1 to be responsible for the RhoA-induced Golgi fragmentation ([@bib68]). Although the inhibition or loss of PKD delayed nocodazole-induced Golgi fragmentation ([@bib20]), we show here that mDia1 is not responsible for PKD activation downstream of Rho. In hippocampal neurons, PKD1 activation at the Golgi occurs via a RhoA/ROCK signaling pathway and is required for the formation of Golgi outposts ([@bib55]). In HeLa cells ROCK1 and 2 were dispensable for RhoA-mediated PKD activation, instead, we identified PLCε as the key Rho effector. The reason(s) underlying the differential regulation of PKD downstream of RhoA in HeLa cells and neurons is not clear at present. Within the PI-PLC family, PLCε has an outstanding role because it is an effector of the small GTPases Rho and Ras and further acts as a GEF protein for Rap1 ([@bib18]; [@bib64]). Stimulated by the direct binding to RhoA, RhoB, or RhoC, PLCε hydrolyzes PtdIns(4,5)P~2~ to generate DAG and IP3 ([@bib65]). In cardiac myocytes PLCε is localized to a perinuclear compartment through binding to a muscle-specific A-kinase anchoring protein β (mAKAPβ) ([@bib66], [@bib67]) and hydrolyzes PtdIns(4)P to generate DAG and IP2 ([@bib67]). Subsequently, the PLCε/DAG-activated PKD translocates to the nucleus and induces the transcription of hypertrophic genes ([@bib67]). Interestingly, PLCε mediates sustained signaling by driving a positive feedback loop through the small GTPase Rap1. Smrcka and colleagues suggested a model in which Rap1 recruits PLCε to the Golgi complex. PLCε in turn activates Rap1, which strengthens the PLCε association with Golgi membranes thereby maintaining local DAG levels ([@bib58]). Intriguingly, Gβγ signaling at the Golgi complex triggered PLCε activation in cardiac myocytes ([@bib67]), however, so far this has not been connected to Rho and/or PKD-dependent vesicle fission at this compartment. Based on our findings we conclude that the DAG pool produced by PLCε is also required for basal and GPCR-induced PKD activity at the TGN, thereby linking GEF-H1-controlled Rho activity with Golgi function and transport.

Thus far, DLC3 is the only RhoGAP protein that has been associated with Golgi membranes. Depletion of DLC3 resulted in Golgi fragmentation, most likely due to enhanced local Rho activity ([@bib9]). We now provide evidence that DLC3 counteracts GEF-H1-mediated Rho and consequently PKD activation at TGN membranes. Furthermore, DLC3 is required for the integrity of the Rab8 compartment ([@bib9]). Loss of DLC3 and therefore increased Rho activity impaired the tubule-like distribution of Rab8 and converted it to a vesicular phenotype with enhanced perinuclear localization. This is consistent with observations by Hattula et al. showing that RhoA G14V expression or nocodazole treatment redistributed Rab8 to the perinuclear region. Remarkably, we observed a similar Rab8 phenotype upon expression of active PKD1 or PKD2 demonstrating that PKD is upstream of Rab8 localization. Rab6 and Rab8 localize to the same Golgi-derived exocytic carriers, with Rab6 controlling Rab8 localization ([@bib24]; [@bib25]; [@bib36]; [@bib62]). We thus hypothesize that PKD is not only required for the fission of these carriers but also responsible for the proper assembly of Rab8 at the TGN. Whether PKD is upstream of Rab6 activity in this process needs to be addressed in the future.

We further provide evidence for the Rho- and PKD-dependent trafficking of TNFα in Rab6 positive vesicles. Our data are thus in line with a previous study showing that Rab6 acts on TNFα trafficking at the level of TGN exit and is required for the efficient post-Golgi transport of TNFα in inflammatory macrophages ([@bib45]). In inflammatory macrophages and monocytes, TNFα secretion is induced by lipopolysaccharides ([@bib45]) and further augmented by thrombin ([@bib32]), respectively, supporting our data that connect GPCR signaling with PKD activation at the TGN. Notably, the exocytosis of TNFα is restricted to FAs (personal correspondence F. Perez (Institute Curie, Paris), November, 2017). Likewise, Rab6-positive vesicles have been associated with the exocytosis of MT1-MMP near FAs ([@bib59]) and a recent report showed for the first time the targeted delivery of integrin-rich vesicles to FAs ([@bib34]) establishing these structures as cellular hot spots of secretion.

Constitutively active RhoA was reported to augment the production of Rab6-positive vesicles ([@bib68]) and Rab6-positive vesicles were shown to move along microtubules targeting FAs, thereby contributing to FA turnover during directed cell migration ([@bib59]). We show here that GEF-H1, PLCε, or PKD are required for the formation and transport of these vesicles. Our results thus provide an explanation for the previously reported effects of GEF-H1 loss on cell spreading and FA turnover ([@bib49]; [@bib60]). Interestingly, extracellular matrix stiffness was found to destabilize microtubules, releasing GEF-H1, which was required for the invasion of breast cancer cells through 3D matrices ([@bib30]). Thus, future studies should address whether microtubules, through Rho-mediated activation of Golgi-localized PKD, sense extracellular matrix density to coordinate Golgi secretory function with the increased demand for factors such as proteases or cytokines required for ECM remodeling during invasive 3D migration.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\   Designation             Source or reference                                                                                                                                   Identifiers                                                                               Additional information
  or resource                                                                                                                                                                                                                                                                                       
  ------------------------- ----------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------------
  Cell line (human)         HEK293T                 ATCC                                                                                                                                                  ATCC Cat\# CRL-3216, RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)           

  Cell line\                Flp-In T-Rex-293        Thermo Fisher Scientific                                                                                                                              RRID:[CVCL_U427](https://scicrunch.org/resolver/CVCL_U427)                                
  (human)                                                                                                                                                                                                                                                                                           

  Cell line\                Flp-In T-Rex-HeLa       other                                                                                                                                                                                                                                           generated by Elena Dobrikova\
  (human)                                                                                                                                                                                                                                                                                           and Matthias Gromeier, Duke\
                                                                                                                                                                                                                                                                                                    University Medical Center,\
                                                                                                                                                                                                                                                                                                    Durham, NC, USA

  Cell line\                HeLa                    ATCC                                                                                                                                                  ATCC Cat\# CRM-CCL-2, RRID:[CVCL_0030](https://scicrunch.org/resolver/CVCL_0030)          
  (human)                                                                                                                                                                                                                                                                                           

  Recombinant\              pEGFP-N1-PKD1\          DOI: 10.1038/ncb1289                                                                                                                                                                                                                            
  DNA reagent               wt/K612W                                                                                                                                                                                                                                                                

  Recombinant\              pEGFP-N1-PKD2           DOI: 10.1038/ncb1289                                                                                                                                                                                                                            
  DNA reagent                                                                                                                                                                                                                                                                                       

  Recombinant\              pCMV5-EGFP-GEF\         DOI: 10.1038/ncb773                                                                                                                                                                                                                             
  DNA reagent               -H1 wt                                                                                                                                                                                                                                                                  

  Recombinant\              pCMV5-EGFP-GEF\         DOI: 10.1038/ncb773                                                                                                                                                                                                                             
  DNA reagent               -H1 C53R                                                                                                                                                                                                                                                                

  Recombinant\              pTriEx-RhoA\            DOI: 10.1038/nature04665                                                                                                                              Addgene \#12150                                                                           
  DNA reagent               FLARE.sc                                                                                                                                                                                                                                                                

  Recombinant\              mRuby-Golgi-7                                                                                                                                                                 Addgene \#55865                                                                           
  DNA reagent                                                                                                                                                                                                                                                                                       

  Recombinant\              Rab6a-GFP               other                                                                                                                                                                                                                                           provided by Francis Barr,\
  DNA reagent                                                                                                                                                                                                                                                                                       Oxford University

  Recombinant\              DsRed2-Paxillin         DOI: 10.1038/ncb1094                                                                                                                                                                                                                            
  DNA reagent                                                                                                                                                                                                                                                                                       

  Recombinant\              G-PKDrep                doi: 10.1111/j.1600--\                                                                                                                                                                                                                          
  DNA reagent                                       0854.2009.00918.x                                                                                                                                                                                                                               

  Recombinant\              Clip170-GFP             other                                                                                                                                                                                                                                           provided by Niels Galjart,\
  DNA reagent                                                                                                                                                                                                                                                                                       Erasmus Medical Center,\
                                                                                                                                                                                                                                                                                                    Rotterdam

  Recombinant\              pcDNA5/FRT/TO-EGFP\     this paper                                                                                                                                                                                                                                      
  DNA reagent               -GEF-H1 wt/C53R                                                                                                                                                                                                                                                         

  Recombinant\              pECFP-Endo/RhoB         Clontech                                                                                                                                              Clontech \#6934--1                                                                        
  DNA reagent                                                                                                                                                                                                                                                                                       

  Recombinant\              pECFP-Endo/Rhob\        this paper                                                                                                                                                                                                                                      site-directed mutagenesis\
  DNA reagent               Q63L                                                                                                                                                                                                                                                                    using pECFP-RhoB as a\
                                                                                                                                                                                                                                                                                                    template

  Recombinant\              pEGFP-RhoB              this paper                                                                                                                                                                                                                                      subcloned from\
  DNA reagent                                                                                                                                                                                                                                                                                       pECFP-Endo/RhoB

  Recombinant\              pEGFP-RhoB Q63L         this paper                                                                                                                                                                                                                                      subcloned from\
  DNA reagent                                                                                                                                                                                                                                                                                       pECFP-Endo/RhoB Q63L

  Recombinant\              pEGFP-RhoA              DOI: 10.1242/jcs.163857                                                                                                                                                                                                                         
  DNA reagent                                                                                                                                                                                                                                                                                       

  Recombinant\              pEGFP-RhoA Q63L         DOI: 10.1242/jcs.163857                                                                                                                                                                                                                         
  DNA reagent                                                                                                                                                                                                                                                                                       

  Recombinant\              pcDNA3.1-HA-RhoA\       DOI: 10.1242/jcs.163857                                                                                                                                                                                                                         
  DNA reagent               Q63L                                                                                                                                                                                                                                                                    

  Recombinant\              pcDNA3.1-HA-RhoA        DOI: 10.1242/jcs.163857                                                                                                                                                                                                                         
  DNA reagent                                                                                                                                                                                                                                                                                       

  Recombinant\              Str-KDEL-TNFa-SBP-\                                                                                                                                                           Addgene \#65279                                                                           
  DNA reagent               mCherry                                                                                                                                                                                                                                                                 

  Recombinant\              pOG44                   Thermo Fisher Scientific                                                                                                                              Thermo Fisher Scientific V600520                                                          
  DNA reagent                                                                                                                                                                                                                                                                                       

  Antibody                  p230                    BD Biosciences                                                                                                                                        BD Biosciences Cat\# 611280, RRID:[AB_398808](https://scicrunch.org/resolver/AB_398808)   

  Antibody                  GFP                     Roche                                                                                                                                                 Sigma-Aldrich\                                                                            
                                                                                                                                                                                                          Cat\# 11814460001,\                                                                       
                                                                                                                                                                                                          RRID:[AB_390913](https://scicrunch.org/resolver/AB_390913)                                

  Antibody                  TGN46                   Bio-Rad/AbD Serotec                                                                                                                                   Bio-Rad/AbD Serotec\                                                                      
                                                                                                                                                                                                          Cat\# AHP500,\                                                                            
                                                                                                                                                                                                          RRID:[AB_324049](https://scicrunch.org/resolver/AB_324049)                                

  Antibody                  alpha-tubulin           Millipore                                                                                                                                             Millipore Cat\# 05--829,\                                                                 
                                                                                                                                                                                                          RRID:[AB_310035](https://scicrunch.org/resolver/AB_310035)                                

  Antibody                  DLC3                    Santa Cruz Biotechnology                                                                                                                              Santa Cruz Biotechnology\                                                                 
                                                                                                                                                                                                          Cat\# sc-166725,\                                                                         
                                                                                                                                                                                                          RRID:[AB_2197829](https://scicrunch.org/resolver/AB_2197829)                              

  Antibody                  PKD1                    Cell Signaling                                                                                                                                        Cell Signaling Technology\                                                                
                                                                                                                                                                                                          Cat\# 2052, RRID:[AB_2268946](https://scicrunch.org/resolver/AB_2268946)                  

  Antibody                  PKD2                    Cell Signaling                                                                                                                                        Cell Signaling Technology\                                                                
                                                                                                                                                                                                          Cat\# 8188S,\                                                                             
                                                                                                                                                                                                          RRID:[AB_10829368](https://scicrunch.org/resolver/AB_10829368)                            

  Antibody                  PKD3                    Cell Signaling                                                                                                                                        Cell Signaling Technology\                                                                
                                                                                                                                                                                                          Cat\# 5655S,\                                                                             
                                                                                                                                                                                                          RRID:[AB_10695917](https://scicrunch.org/resolver/AB_10695917)                            

  Antibody                  GEF-H1                  Cell Signaling                                                                                                                                        Cell Signaling Technology\                                                                
                                                                                                                                                                                                          Cat\# 4076, RRID:[AB_2060032](https://scicrunch.org/resolver/AB_2060032)                  

  Antibody                  phospho-PKD\            Cell Signaling                                                                                                                                        Cell Signaling Technology\                                                                
                            (Ser744/748)                                                                                                                                                                  Cat\# 2054S,\                                                                             
                                                                                                                                                                                                          RRID:[AB_2172539](https://scicrunch.org/resolver/AB_2172539)                              

  Antibody                  Rab8                    Cell Signaling                                                                                                                                        Cell Signaling Technology\                                                                
                                                                                                                                                                                                          Cat\# 6975S,\                                                                             
                                                                                                                                                                                                          RRID:[AB_10827742](https://scicrunch.org/resolver/AB_10827742)                            

  Antibody                  Rab6                    Cell Signaling                                                                                                                                        Cell Signaling Technology\                                                                
                                                                                                                                                                                                          Cat\# 9625S,\                                                                             
                                                                                                                                                                                                          RRID:[AB_10971791](https://scicrunch.org/resolver/AB_10971791)                            

  Antibody                  pS910                   DOI: 10.1083/jcb.200110047                                                                                                                                                                                                                      

  Antibody                  ERK1/2                  Cell Signaling                                                                                                                                        Cell Signaling Technology\                                                                
                                                                                                                                                                                                          Cat\# 9107S,\                                                                             
                                                                                                                                                                                                          RRID:[AB_10695739](https://scicrunch.org/resolver/AB_10695739)                            

  Antibody                  MEK1/2                  Cell Signaling                                                                                                                                        Cell Signaling Technology\                                                                
                                                                                                                                                                                                          Cat\# 8727,\                                                                              
                                                                                                                                                                                                          RRID:[AB_10829473](https://scicrunch.org/resolver/AB_10829473)                            

  Antibody                  pERK1/2\                Cell Signaling                                                                                                                                        Cell Signaling Technology\                                                                
                            (Thr202/Tyr204)                                                                                                                                                               Cat\# 4094S,\                                                                             
                                                                                                                                                                                                          RRID:[AB_10694057](https://scicrunch.org/resolver/AB_10694057)                            

  Antibody                  pMEK1/2\                Cell Signaling                                                                                                                                        Cell Signaling Technology\                                                                
                            (Ser2017/221)                                                                                                                                                                 Cat\# 9154,\                                                                              
                                                                                                                                                                                                          RRID:[AB_2138017](https://scicrunch.org/resolver/AB_2138017)                              

  Antibody                  ROCK1                   Millipore                                                                                                                                             Millipore Cat\# 04--1121,\                                                                
                                                                                                                                                                                                          RRID:[AB_1977472](https://scicrunch.org/resolver/AB_1977472)                              

  Antibody                  ROCK2                   BD Biosciences                                                                                                                                        BD Biosciences Cat\# 610623,\                                                             
                                                                                                                                                                                                          RRID:[AB_397955](https://scicrunch.org/resolver/AB_397955)                                

  Antibody                  pS294                   DOI: 10.1038/ncb1289                                                                                                                                                                                                                            IF 1:750

  Antibody                  HRP goat anti-rabbit    Dianova                                                                                                                                               Jackson ImmunoResearch\                                                                   
                                                                                                                                                                                                          Labs Cat\# 111-035-144,\                                                                  
                                                                                                                                                                                                          RRID:[AB_2307391](https://scicrunch.org/resolver/AB_2307391)                              

  Antibody                  HRP goat anti-mouse     Dianova                                                                                                                                               Jackson ImmunoResearch\                                                                   
                                                                                                                                                                                                          Labs Cat\# 115-035-062,\                                                                  
                                                                                                                                                                                                          RRID:[AB_2338504](https://scicrunch.org/resolver/AB_2338504)                              

  Antibody                  Alexa Fluor labelled\   Thermo Fisher Scientific                                                                                                                              Thermo Fisher Scientific                                                                  
                            secondary antibodies                                                                                                                                                                                                                                                    

  Sequence-based\           ON-Targetplus\          Dharmacon                                                                                                                                             Dharmacon                                                                                 
  reagent                   smartpools                                                                                                                                                                                                                                                              

  Sequence-based\           Silencer select\        Thermo Fisher Scientific                                                                                                                              Thermo Fisher Scientific\                                                                 
  reagent                   siPLCe                                                                                                                                                                        s27660                                                                                    

  Sequence-based\           Silencer select\        Thermo Fisher Scientific                                                                                                                              Thermo Fisher Scientific\                                                                 
  reagent                   siGEF-H1                                                                                                                                                                      s17546                                                                                    

  Sequence-based\           Quantitect primers\     Qiagen                                                                                                                                                Qiagen                                                                                    
  reagent                   for RT-PCR                                                                                                                                                                                                                                                              

  Peptide, recombinant\     Trypsin                 Thermo Fisher Scientific                                                                                                                              Thermo Fisher Scientific\                                                                 
  protein                                                                                                                                                                                                 15090046                                                                                  

  Peptide, recombinant\     Thrombin                Millipore                                                                                                                                             Millipore 605195                                                                          
  protein                                                                                                                                                                                                                                                                                           

  Commercial assay\         QuantiTect SYBR\        Qiagen                                                                                                                                                Qiagen 204243                                                                             
  or kit                    Green RT-PCR Kit                                                                                                                                                                                                                                                        

  Commercial assay\         Rneasy plus Kit         Qiagen                                                                                                                                                Qiagen 74104                                                                              
  or kit                                                                                                                                                                                                                                                                                            

  Chemical compound,\       Nocodazole              Sigma-Aldrich                                                                                                                                         Sigma-Aldrich M1404                                                                       
  drug                                                                                                                                                                                                                                                                                              

  Chemical compound,\       CRT0066101              Tocris Bioscience                                                                                                                                     Tocris Bioscience 4975                                                                    
  drug                                                                                                                                                                                                                                                                                              

  Chemical compound,\       H1152                   Enzo Life Science                                                                                                                                     Enzo Life Science\                                                                        
  drug                                                                                                                                                                                                    ALX-270--423 M001                                                                         

  Chemical compound,\       UO126                   Cell Signaling                                                                                                                                        Cell Signaling \#9903                                                                     
  drug                                                                                                                                                                                                                                                                                              

  Chemical compound,\       Blasticidin             Thermo Fisher Scientific                                                                                                                              Thermo Fisher Scientific\                                                                 
  drug                                                                                                                                                                                                    R21001                                                                                    

  Chemical compound,\       Hygromycin B            Thermo Fisher Scientific                                                                                                                              Thermo Fisher Scientific\                                                                 
  drug                                                                                                                                                                                                    10687010                                                                                  

  Chemical compound,\       Doxycyclin              Sigma-Aldrich                                                                                                                                         Sigma-Aldrich D9891                                                                       
  drug                                                                                                                                                                                                                                                                                              

  Chemical compound,\       Zeocin                  Thermo Fisher Scientific                                                                                                                              Thermo Fisher Scientific\                                                                 
  drug                                                                                                                                                                                                    R25001                                                                                    

  Chemical compound,\       Collagen R              Serva                                                                                                                                                 Serva 47254                                                                               
  drug                                                                                                                                                                                                                                                                                              

  Chemical compound,\       Biotin                  Sigma-Aldrich                                                                                                                                         Sigma-Aldrich B4501                                                                       
  drug                                                                                                                                                                                                                                                                                              

  Chemical compound,\       Blocking reagent        Roche                                                                                                                                                 Roche 11096176001                                                                         
  drug                                                                                                                                                                                                                                                                                              

  Software, algorithm       Cell Profiler           <http://cellprofiler.org>                                                                                                                             CellProfiler Image\                                                                       
                                                                                                                                                                                                          Analysis Software,\                                                                       
                                                                                                                                                                                                          RRID:[SCR_007358](https://scicrunch.org/resolver/SCR_007358)                              

  Software, algorithm       GraphPad Prism          GraphPad Prism (<https://graphpad.com>)                                                                                                               Graphpad Prism,\                                                                          
                                                                                                                                                                                                          RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                              

  Software, algorithm       Image Studio\           <https://www.licor.com/bio/products/software/image_studio_lite/?utm_source=BIO+Blog&utm_medium=28Aug13post&utm_content=ISLite1&utm_campaign=ISLite>   Image Studio Lite,\                                                                       
                            Lite 4.0                                                                                                                                                                      RRID:[SCR_014211](https://scicrunch.org/resolver/SCR_014211)                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Reagents, plasmids, antibodies {#s4-1}
------------------------------

The plasmid encoding G-PKDrep was described previously ([@bib20]). Cherry-tagged G-PKDrep was generated by replacing GFP with mCherry. Plasmids encoding GFP-tagged PKD1 wt, kd PKD1 K612W, and GFP-tagged PKD2 were described previously ([@bib29]). The RhoA WT biosensor pTriEx-RhoA FLARE.sc was purchased from Addgene (Addgene plasmid \# 12150; \[[@bib53]\]). mRuby-Golgi-7 (N-terminal 81 amino acids of human *β*−1,4-galactosyltransferase) was a gift from Michael Davidson (Addgene plasmid \# 55865). The plasmid encoding Rab6a-GFP was provided by Francis Barr (Oxford University), DsRed2-paxillin was received from Rick Horwitz (University of Virginia). Plasmids encoding GFP-tagged GEF-H1 wt and C53R were provided by Perihan Nalbant (University of Duisburg-Essen) and are described in detail in ([@bib40]). pEGFP-RhoA Q63L and pcDNA3.1-HA-RhoA constructs were described elsewhere ([@bib9]). Clip170-GFP was a kind gift from N. Galjart (Erasmus Medical Center, Rotterdam, The Netherlands). The pECFP-RhoB/Endo vector was purchased from Clontech (Mountainview, CA, USA, Clontech plasmid \#6934--1). pEGFP-RhoB was generated by subcloning of RhoB into the pEGFP vector. The mutation Q63L was inserted by site-directed mutagenesis using the primers RhoB Q63L FP 5' gtgggacacagctggcctggaggactacgaccgc 3' and RhoB Q63L RP 5' gcggtcgtagtcctccaggccagctgtgtcccac 3' (purchased from Eurofins Genomics, Ebersberg, Germany). To generate the inducible GEF-H1 expression plasmids pcDNA5/FRT/TO-EGFP-GEF-H1 wt and pcDNA5/FRT/TO-EGFP-GEF-H1 C53R, the cDNA encoding GFP-GEF-H1 was excised from the pCMV5-EGFP-GEF-H1 plasmid with *EcoRI and HindIII,* and, after DNA blunting, ligated with pcDNA5/FRT/TO digested with *EcoRV*. Integrity of the construct was verified by sequencing. The pSer294-specific rabbit polyclonal antibody used for detection of G-PKDrep phosphorylation was described before ([@bib20]). The antibody specific for PKD1 autophosphorylation at serine 910 has been described elsewhere ([@bib28]). Commercially available antibodies used were as follows: TGN46-specific sheep antibody was from Bio-RAD. The following antibodies were from Cell Signaling Technologies (Danvers, MA, USA): anti-Rab8, anti-Rab6, anti-PKD2, anti-PKD3, anti-GEF-H1 rabbit monoclonal antibodies and anti-phospho-PKD (Ser744/748) and anti-PKD1 rabbit antibodies, mouse mAb ERK1/2 (3A7), rabbit mAb MEK1/2 (D1A5), rabbit mAb pERK1/2 (Thr202/Tyr204) (D13.14.4E), rabbit mAb pMEK1/2 (Ser217/221) (41G9). The ROCK1-specific rabbit monoclonal antibody EPR638Y was from Merck Chemicals, anti-ROCK2 mouse monoclonal antibody clone 21 was from BD Biosciences, monoclonal mouse anti-DLC3 (E-2) (Santa Cruz Biotechnology, Dallas, Texas, USA), anti--tubulin α mouse monoclonal antibody (Merck Chemicals GmbH, Darmstadt, Germany), anti-p230 (BD Biosciences, Heidelberg, Germany), and anti-GFP mouse monoclonal antibody (Roche Diagnostics). Secondary antibodies used were Alexa405, Alexa488, Alexa546, or Alexa633 coupled goat anti--mouse and anti--rabbit immunoglobulin G (IgG) (Life Technologies, Carlsbad, CA, USA), and horseradish peroxidase (HRP) coupled goat anti--mouse and anti--rabbit IgG (Dianova, Hamburg, Germany). Alexa633-coupled phalloidin was obtained from Life Technologies. Nocodazole was obtained from Sigma-Aldrich, trypsin was from Thermo Fisher Scientific, thrombin from Merck Millipore, UO126 was obtained from Cell Signaling Technologies. H1152 was from Enzo Life Science (Farmingdale, NY, USA). CRT0066101 was from Tocris Bioscience (Bristol, UK).

Protein extraction of cells and Western blotting {#s4-2}
------------------------------------------------

Whole cell extracts were obtained by solubilizing cells in lysis buffer (20 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM ethylene glycol tetra acetic acid (EGTA), plus Complete protease inhibitors and PhosSTOP (Roche Diagnostics, Basel, Switzerland)). Whole cell lysates were clarified by centrifugation for 15 min at 16,000 g and 4°C. Equal amounts of protein were loaded on 10% polyacrylamide gels or were run on NuPage Novex 4--12% Bis-Tris or 3--8% Tris-Acetate gels (Life Technologies) and blotted onto nitrocellulose membranes using the iBlot device (Life Technologies). Membranes were blocked for 30 min with 0.5% (v/v) blocking reagent (Roche Diagnostics) in PBS containing 0.05% (v/v) Tween-20. Membranes were incubated with primary antibodies overnight at 4°C, followed by 1 hr incubation with HRP-conjugated secondary antibodies at room temperature. Proteins were visualized using an enhanced chemiluminescence detection system (Thermo Fisher Scientific, Waltham, MA, USA). For quantitative Western Blotting chemiluminescence was detected at a depth of 16-bit in the linear detection range of an Amersham Imager 600 equipped with a 3.2 megapixel super-honeycomb CCD camera fitted with a large aperture f/0.85 FUJINON lens. Special care was taken not to overexpose in order to guarantee accurate quantifications. For all proteins, at least three independent membranes were analyzed. Densitometry was performed using Image Studio Lite 4.0 (Li-COR Biosciences, Bad Homburg, Germany). For each protein, the integrated density of the signal was measured, corrected for background signals and adjusted to loading controls.

Cell culture and transfection {#s4-3}
-----------------------------

HeLa and HEK293T cells were maintained in RPMI 1640 medium supplemented with 10% FCS. Cell lines were authenticated using Multiplex Cell Authentication by Multiplexion (Heidelberg, Germany) as described recently ([@bib12]). The SNP profiles matched known profiles or were unique. Cells were tested negative for mycoplasma contamination using MycoAlert (Lonza, Switzerland). For transient plasmid transfections, HEK293T cells were transfected with TransIT-293 (Mirus Bio, Madison, WI, USA). HeLa cells were transfected with TransIT-HeLaMONSTER (Mirus Bio) or in case of RUSH experiments with FuGENE HD transfection reagent (Promega, Madison, WI, USA) according to the manufacturer's instructions. In the case of siRNA oligonucleotides, HEK293T and HeLa cells were transfected with Lipofectamine RNAimax (Life Technologies) according to the manufacturer's instructions. After 48 hr, siRNA-transfected cells were further transfected with plasmid DNA and analyzed 24 hr later. As a negative control (termed spNT), ON-TARGETplus non-targeting control pool D-001810--10 from Dharmacon (Lafayette, CO, USA) was used. siRNAs used were: spDLC3 (siGENOME SMARTpool human STARD8 M-010254), spmDia1 (ON-Target plus SMARTpool human DIAPH1, L-010347), spGEF-H1 (ON-Target plus SMARTpool human ARHGEF2 L-009883), spPLCε(ON-Target plus SMARTpool human PLCE1 J-004201), spPKD2 (ON-Target plus SMARTpool human PRKD2 L-004197, spPKD3 (ON-Target plus SMARTpool human PRKD3 L-005029), spROCK1 (ON-Target plus SMARTpool human ROCK1 L-003536), and spROCK2 (ON-Target plus SMARTpool human ROCK2 L-004610). All smartpools were obtained from Dharmacon. The following single siRNAs were obtained from Thermo Fisher Scientific: siPLCε (Silencer Select s27660) and siGEF-H1 (Silencer Select s17546). Flp-In T-REx-293 cells (Life Technologies) and Flp-In T-REx-HeLa cells (generated by Elena Dobrikova and Matthias Gromeier, Duke University Medical Center, Durham, NC, USA) were grown in DMEM containing 10% FCS, 100 μg/ml zeocin and 15 μg/ml (293) or 10 µg/ml blasticidin (HeLa). These cells stably express the Tet repressor, contain a single Flp Recombination Target (FRT) site and were used to generate the Flp-In-T-REx-EGFP-GEF-H1- lines. Cells were cotransfected with pcDNA5/FRT/TO-EGFP-GEF-H1 wt or C53R and the Flp recombinase expression plasmid pOG44 at a ratio of 1:10 and then selected with 100 μg/ml (293) or 500 µg/ml (HeLa) hygromycin B. Induction of protein expression with doxycycline was at 10 ng/ml. Treatment of cells with nocodazole was at 5 µg/ml, trypsin and thrombin were used at 10 nM.

Quantitative one-step real-time PCR {#s4-4}
-----------------------------------

RNA was isolated from cells using the RNeasy plus Kit (Qiagen, Hilden, Germany) following the manufacturers' instructions. 100 ng RNA were used for the real-time PCR reaction using the QuantiTect SYBR Green RT-PCR Kit from Qiagen following the manufacturer's instructions. Analysis was performed using the CFX96 Touch Real-Time PCR Detection System (Bio-RAD, Hercules, CA, USA). The following QuantiTect primers were used: Hs_GAPDH_2\_SG , Hs_PLCE1_1\_SG, Hs_ARHGEF2_1\_SG, Hs_PRKD2_1\_SG, Hs_PRKD3_1\_SG, and Hs_ACTB_2\_SG (all obtained from Qiagen).

Immunofluorescence staining and confocal microscopy {#s4-5}
---------------------------------------------------

Cells grown on glass coverslips coated with 2,5 µg/ml collagen R (Serva, Heidelberg, Germany) were fixed for 15 min with 4% (v/v) paraformaldehyde. After washes in PBS, cells were incubated for 5 min with 1 M glycine in PBS and permeabilized for 2 min with 0.1% (v/v) Triton X-100 in PBS. Blocking was performed with 5% (v/v) bovine serum (PAN) in PBS for 30 min. Fixed cells were incubated with primary antibodies diluted in blocking buffer for 2 hr at room temperature. Following three washing steps with PBS, cells were incubated with Alexa-Fluor-(488, 546 or 633)-labeled secondary antibodies in blocking buffer for 1 hr at room temperature. Nuclei were counterstained with DAPI and mounted in ProLong Gold Antifade Reagent (Thermo Fisher Scientific). All samples were analyzed at room temperature using a confocal laser scanning microscope (LSM 710, Carl Zeiss) equipped with a Plan Apochromat 63x/1.40 DIC M27 (Carl Zeiss, Jena, Germany) oil-immersion objective. GFP was excited with the 488 nm line of an Argon laser, its emission was detected from 496 to 553 nm. Alexa546 was excited with a 561 nm DPSS laser, its emission was detected from 566 to 622 nm. In case of Phalloidin-Alexa633 staining, Alexa633 was excited with a 633 nm HeNe laser, its emission was detected from 638 to 740 nm. Image acquisition for G-PKDrep ratiometric imaging was done as follows: z-stacks of 0.5 µm intervals were acquired throughout the cell and maximum intensity projections were calculated. GFP and Alexa546 channels were hereby acquired with the same pinhole setting that was adjusted to 1 AU in the Alexa 546 channel. Laser powers were adjusted to prevent fluorophore saturation and identical photomultiplier tube and laser settings were maintained throughout the whole experiment. Image processing and analysis was performed with Zen black 2.1 software. Regions of interest of identical Golgi areas of reporter expressing cells were selected in the GFP channel, mean pixel intensity values of the selected areas in both channels were measured and the Alexa546 to GFP ratio was calculated. In the case of the Cherry-tagged G-PKDrep construct, staining of the pSer294 signal was performed using an Alexa633-conjugated secondary antibody. Image acquisition was done in the Cherry and Alexa633 channels as described above. Alexa633 pixel intensity was corrected for background signals.

FRET imaging {#s4-6}
------------

FRET studies with the RhoA activity biosensor were performed on a Zeiss Axio Observer Spinning Disc microscope equipped with a Plan-Apochromat 63x/1.4 Oil DIC objective and a Photometrix Evolve 512 EMCCD camera. CFP and FRET channels were acquired with a 445 nm diode excitation laser combined with 485/30 nm (CFP) and 562/45 nm (FRET) emission filters. mRuby was acquired using a 561 nm diode excitation laser combined with a 600/50 nm emission filter. Images were acquired at 37°C every 60 s for one hour at a resolution of 512 × 512 Px. Focus was stabilized using the Definite Focus 2 autofocus device. Nocodazole was added 10 min after start of image acquisition. Image analysis was done with Zen blue 2.3 software. After background subtraction the mean FRET/CFP (Y/C) emission ratio was calculated for every time point. In order to measure RhoA activity specifically at the Golgi complex, a ROI was drawn around the Golgi compartment (identified through the mRuby-Golgi7 signal). The mean FRET/CFP emission ratio of the ROI of multiple cells was normalized to its values in unstimulated state and plotted against the time. In parallel, ratio images that reflect the RhoA activation state throughout the cell were generated.

TIRF microscopy {#s4-7}
---------------

TIRF images were acquired on the same Zeiss Axio Observer microscope stand used for FRET imaging, additionally equipped with a motorized TIRF illuminator (Laser TIRF 3), an EMCCD camera (Photometrics Evolve 512) and an alpha Plan-Apochromat 100x/1.46 NA Oil objective at 37°C and 5% CO~2~ in phenolred-free RPMI supplemented with 10% FCS. In case of the basal localized delivery experiment, TIRF-images of GFP-Rab6 and DsRed2-Paxillin were acquired every second for a time interval of two minutes. Image processing was done with the Zen 2.1 blue software. All channels were filtered with a Low-pass filter followed by an unsharp-masking in order to reduce pixel noise and enhance the contrast of dim structures. In case of the thrombin stimulation, cells were serum starved for 30 min prior to image acquisition. TIRF images were acquired every two seconds for a time interval of 35 min. Thrombin was added after 5 min. Control cells received PBS. Kymographs were generated using Zen 2.3 blue software. For each cell, three to five kymographs were generated. At least 10 focal adhesions per cell were analyzed for vesicle arrival.

3D time lapse {#s4-8}
-------------

3D time lapse studies were performed on the Zeiss Axio Observer Spinning Disc system equipped with a Plan-Apochromat 63x/1.4 Oil DIC objective and two Axiocam 503 mono CCD cameras. GFP-Rab6A and DsRed2-Paxillin images were acquired simultaneously in Dual-camera mode using a 560 nm beamsplitter. The following excitation lasers and emission filters were used: GFP, 488 nm diode laser, 525/50 nm filter, RFP, 561 nm (RFP) diode laser, 600/50 nm filter. Z-Stacks with a 500 nm interval were acquired every second for two minutes. 3D time lapse sequences were rendered using the Zen blue 2.1 3d VisArt module.

Golgi localization analysis {#s4-9}
---------------------------

Images for Golgi localization analysis were acquired on the LSM710 microscope equipped with an EC-Plan Neofluar 40x/1.30 NA Oil DIC objective. GFP and Alexa 546 images were acquired with the same settings as described confocal microscopy section. Quantitative image analysis was done with CellProfiler version 2.1.1 ([@bib11]; [@bib38]). Ten confocal overview images (zoom factor 0.6) were analyzed per condition. The Golgi complex and the cytoplasm were segmented using the p230 staining and its background, respectively. The mean intensity of the GFP signal was measured under both segmentation masks and the Golgi/Cytoplasm ratio was generated for every cell representing the PKD1kd-GFP distribution throughout the cell. GFP-negative cells were excluded from the analysis.

Kymography {#s4-10}
----------

Microtubuli polymerization studies were performed on the Zeiss Axio Observer Spinning Disc system equipped with a Plan-Apochromat 63x/1.4 Oil DIC objective and two Axiocam 503 mono CCD cameras. Clip170-GFP and DsRed2-Paxillin were acquired sequentially every second for 2 min using an automated emission filter wheel for CSU-X1. The following excitation lasers and emission filters were used: GFP, 488 nm diode laser, 525/50 nm filter, RFP, 561 nm (RFP) diode laser, 600/50 nm filter. Kymographs were generated in the Zen blue 2.1 software.

Golgi co-localization analysis {#s4-11}
------------------------------

For the Rab6 and Rab8 Golgi co-localization analysis, HeLa control- and siRNA knockdown cells, overexpressing GFP or a GFP-tagged version of PKD1 or PKD2 were plated on coverslips, fixed and stained for p230 and Rab6 or Rab8 according to the protocol described in the immunofluorescence staining section. For image acquisition, overview images with maximal field of view were taken at a resolution of 2048 × 2048 on the LSM710 microscope equipped with a Plan-Apochromat 63x/1.40 Oil DIC objective. GFP, Alexa 546 and Alexa 633 channels were acquired with the same settings as described in the confocal microscopy section. The quantitative object-based co-localization analysis was done using CellProfiler version 2.1.1 ([@bib11]; [@bib38]). In brief, Golgi complexes were segmented and measured for GFP and Rab6 or Rab8 staining intensities. Each Golgi was then classified in order to be positive or negative for PKD and/or Rab6 and Rab8 using a threshold based cut-off line. For co-localization analysis of RhoA and RhoB with Rab6, HeLa cells were transiently transfected with a GFP-tagged version of RhoA/B wt or Q63L. Cells were plated on coverslips, fixed and stained for Rab6 (Alexa 633) as described in the immunofluorescence staining section. Optical slices were acquired at the LSM710 confocal microscope in all four channels as described in the confocal microscopy section. The quantitative co-localization analysis was performed with CellProfiler software (version 3.0.0). First, single cells were segmented based on the GFP image. Afterwards, Manders' coefficient (Costes automated threshold) was determined for the GFP and Alexa633 overlap in each cell.

RUSH (Retention using selective hooks) trafficking assay {#s4-12}
--------------------------------------------------------

HeLa cells were maintained in biotin-free DMEM supplemented with 10% FCS. SiRNA-transfected cells were plated on glass coverslips and transiently co-transfected with a plasmid encoding Str-KDEL-TNFα-SBP-mCherry ([@bib8]) together with Rab6-GFP at a ratio of 4:1 using FuGENE HD transfection reagent (Promega) according to the manufacturer´s protocol. After biotin-induced release of the TNFα-mCherry cargo from the ER, cells were incubated for 60 min at 19°C to block cargo exit from the Golgi complex. Cargo was released from the Golgi through a temperature shift to 37°C using pre-warmed medium. Cells were fixed at time points 0 and 35 min after release. Samples were stained for the TGN marker p230 using an Alexa405-labelled secondary antibody. Images were acquired at the AxioObserver SD described above. Z-Stacks were acquired with the 63x objective in 405, GFP and Cherry channels at a 500 nm interval and maximum intensity projections were calculated. Only cells expressing Rab6-GFP and TNFα-mCherry at a moderate level were analyzed. The trafficking status of TNFα-mCherry was analyzed and thereby each cell was classified in two categories: 1. 'Golgi' cells, in which the TNF-cargo remained partially at the Golgi compartment. 2. 'Traffic' cells, in which the TNF-cargo exited the Golgi completely. For live cell imaging siRNA-transfected cells were plated in 35 mm glass bottom petri dishes and transiently transfected with the Str-KDEL-TNFα-SBP-mCherry plasmid using FuGENE HD transfection reagent. Cells were imaged in FluoroBrite DMEM (Thermo Fisher Scientific) supplemented with 10% FCS. Time series of images were acquired at the AxioObserver SD described above equipped with an Evolve 512 EMCCD camera (Photometrics, Tucson, AZ, USA). Z-Stacks were acquired with the 63x objective in the Cherry channel at a 500 nm interval every minute for 2 hr. Cargo release from the ER was induced by the addition of biotin at 40 µM after 10 cycles. For image analysis maximum intensity projections were calculated and the mean intensity in the Golgi region was measured over time. The obtained intensities were normalized to the highest value that was considered as the starting point to observe the Golgi traffic to the plasma membrane for each cell.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"A Rho signaling network links microtubules to PKD controlled carrier transport to focal adhesions\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Suzanne Pfeffer as the Reviewing Editor and Vivek Malhotra as the Senior Editor. The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This manuscript investigates the RhoA-dependent activation of PKD at the Golgi. While RhoA has been observed at the Golgi over a decade, it has not been clear what this small GTPase is doing at this location. The current work establishes a RhoA-PLCε-PKD signaling cascade that operates at the Golgi and is important for maintaining Golgi structure and for the export of Rab6 carriers from this organelle. The work is important but the following issues should be addressed before publication can be recommended.

1\) The most important concern is whether the pathway studied is truly physiological. For example, the experiment in Figure 4C, in which PKD activity is assessed under basal conditions (i.e., not treated with nocodazole, trypsin, or GTP-locked RhoA), indicates that PLCε plays only a very minor role in basal PKD activity. Does PAR activation actually alter secretion level (e.g. of TNFα)? If so, then to what extent is the level changed? And, what is a likely physiological context for this regulation? There are many papers showing the impact of altering intracellular signaling factors (including the ones studied here) on secretory pathway organization and/or function. What is missing is a demonstration that these changes occur in a physiologically relevant signaling condition with the expected changes in output (i.e. added ligand X causing a Y-fold change in localized secretion of Z). Here, we believe it would greatly improve the impact of the study to at least quantify PKD-dependent secretion of TNFα in response to activation of a PAR (one wishes something more selective than trypsin could be used for the activation).

2\) The FRET experiment in Figure 2D shows that depletion of GEF-H1 results in a reduction in the total cellular activity of RhoA (lower panel). Therefore, GEF-H1 does not seem to be a Golgi-specific regulator of RhoA. In the upper row of the same panel, treatment with nocodazole also increases total cellular RhoA FRET (i.e. activity). It is hard to see the Golgi in this image, most likely because of fragmentation induced my microtubule depolymerization. It is hard to see Golgi-localized FRET signals in the images provided, even zoomed in. Based on this experiment it is not possible to say that GEF-H1 regulates RhoA activity at the Golgi. Rather, GEF-H1 regulates the total cellular pool of active RhoA, including the Golgi pool.

3\) Is GEF-H1 localized at the Golgi? Also, in Figure 1C, the GFP-RhoA-Q63L image shows that this fusion protein localizes to the Golgi in only a subset of the cells. The extent of Golgi localization should be quantified and reported. It appears that the corresponding RhoB construct has much better Golgi localization.

4\) The G-PKDrep reporter is heavily utilized in this work, and has been previously validated. However, when new treatments are used that have not previously been validated, it is important to verify that the reporter is indeed reporting PKD activity, as it is easy to imagine that another kinase could phosphorylate the reporter. For example, how do we know that GTP-locked RhoA does not activate another kinase that is able to phosphorylate the G-PKDrep reporter? Or that Trypsin treatment doesn\'t activate another kinase that will phosphorylate the reporter? Therefore, for any new experimental treatments involving this reporter, the authors need to do a control where they demonstrate PKD-dependence of the observed increase in reporter signal by including a PKD-knockdown control.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"A Rho signaling network links microtubules to PKD controlled carrier transport to focal adhesions\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Vivek Malhotra as the Senior Editor, Suzanne Pfeffer as the Reviewing Editor, and three reviewers.

We would like to publish your paper but one reviewer wrote,\"... in their response to point 2, they claim that they have toned down the message that GEF-H1 mediates activation of RhoA at the Golgi. I do not see a clear indication for this. The reader is still led to believe that GEF-H1 specifically regulates the Golgi pool of RhoA. This is strange because the authors concede that GEF-H1 regulates RhoA in the entire cell, including the Golgi pool.\" If you can add a few words to make sure this is clarified, we will be delighted to publish your paper in *eLife*.
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Author response

> This manuscript investigates the RhoA-dependent activation of PKD at the Golgi. While RhoA has been observed at the Golgi over a decade, it has not been clear what this small GTPase is doing at this location. The current work establishes a RhoA-PLCε-PKD signaling cascade that operates at the Golgi and is important for maintaining Golgi structure and for the export of Rab6 carriers from this organelle. The work is important but the following issues should be addressed before publication can be recommended.
>
> 1\) The most important concern is whether the pathway studied is truly physiological. For example, the experiment in Figure 4C, in which PKD activity is assessed under basal conditions (i.e., not treated with nocodazole, trypsin, or GTP-locked RhoA), indicates that PLCε plays only a very minor role in basal PKD activity. Does PAR activation actually alter secretion level (e.g. of TNFα)? If so, then to what extent is the level changed? And, what is a likely physiological context for this regulation? There are many papers showing the impact of altering intracellular signaling factors (including the ones studied here) on secretory pathway organization and/or function. What is missing is a demonstration that these changes occur in a physiologically relevant signaling condition with the expected changes in output (i.e. added ligand X causing a Y-fold change in localized secretion of Z). Here, we believe it would greatly improve the impact of the study to at least quantify PKD-dependent secretion of TNFα in response to activation of a PAR (one wishes something more selective than trypsin could be used for the activation).

Basal and stimulus dependent PKD activity at the Golgi are dependent on the amount of DAG in TGN membranes. There are several pathways, e.g. ceramide transfer from the ER or the PLC-mediated hydrolysis of PI4P or PI4,5P2 that contribute to the DAG level at this organelle. These different sources of DAG provide an explanation for the modest but significant contribution of PLCε to basal PKD activity as shown in Figure 4C.

To use a more selective and physiological stimulus for the PAR receptors, in the revised manuscript, we treated cells expressing the PKD reporter with thrombin. Our data clearly show that thrombin activates PKD at the Golgi complex (new Figure 4---figure supplement 1). Most importantly, using TIRF kymography, we show that thrombin stimulates the localized exocytosis of Rab6 vesicles at FA in a PKD-dependent manner (new Figure 7E). Previous reports describing thrombin-induced, Rab6-dependent stimulation of TNFα secretion in monocytes support the physiological relevance of a pathway that links PAR signaling with GEF-H1-dependent PKD activation at the TGN (see Discussion of the revised manuscript).

> 2\) The FRET experiment in Figure 2D shows that depletion of GEF-H1 results in a reduction in the total cellular activity of RhoA (lower panel). Therefore, GEF-H1 does not seem to be a Golgi-specific regulator of RhoA. In the upper row of the same panel, treatment with nocodazole also increases total cellular RhoA FRET (i.e. activity). It is hard to see the Golgi in this image, most likely because of fragmentation induced my microtubule depolymerization. It is hard to see Golgi-localized FRET signals in the images provided, even zoomed in. Based on this experiment it is not possible to say that GEF-H1 regulates RhoA activity at the Golgi. Rather, GEF-H1 regulates the total cellular pool of active RhoA, including the Golgi pool.

Indeed, the FRET data show that nocodazole treatment promotes Rho activity not only at Golgi membranes but also in the periphery in a GEF-H1 dependent manner. We also mention this in the manuscript. We agree with the reviewers that GEF-H1 seems to regulate different Rho pools and have thus changed the phrasing in the Results section. We have also included this point in the Discussion section.

> 3\) Is GEF-H1 localized at the Golgi? Also, in Figure 1C, the GFP-RhoA-Q63L image shows that this fusion protein localizes to the Golgi in only a subset of the cells. The extent of Golgi localization should be quantified and reported. It appears that the corresponding RhoB construct has much better Golgi localization.

In the new Figure 1---figure supplement 1 we provide quantitative data (Manders coefficient) showing that RhoA and RhoB co-localize with Golgi-localized Rab6 to a similar extent. However, active RhoA and RhoB show significantly higher co-localization compared to their wt counterparts. This also supports a role for active Rho at TGN membranes.

> 4\) The G-PKDrep reporter is heavily utilized in this work, and has been previously validated. However, when new treatments are used that have not previously been validated, it is important to verify that the reporter is indeed reporting PKD activity, as it is easy to imagine that another kinase could phosphorylate the reporter. For example, how do we know that GTP-locked RhoA does not activate another kinase that is able to phosphorylate the G-PKDrep reporter? Or that Trypsin treatment doesn\'t activate another kinase that will phosphorylate the reporter? Therefore, for any new experimental treatments involving this reporter, the authors need to do a control where they demonstrate PKD-dependence of the observed increase in reporter signal by including a PKD-knockdown control.

To show PKD-specific phosphorylation of the reporter we now provide data showing that pharmacological inhibition of PKD using the pan-PKD inhibitor CRT0066101 completely abrogates the thrombin and trypsin induced phosphorylation of the reporter (new Figure 4---figure supplement 1).

We also show that the depletion of PKD2 and PKD3 significantly decreases trypsin-induced reporter phosphorylation compared to control cells, proving PKD specificity of the reporter (Figure 4F). The greater variance in the signal compared to pharmacological inhibition can be explained by the different transfection efficiency of the siRNAs.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> We would like to publish your paper but one reviewer wrote,\"... in their response to point 2, they claim that they have toned down the message that GEF-H1 mediates activation of RhoA at the Golgi. I do not see a clear indication for this. The reader is still led to believe that GEF-H1 specifically regulates the Golgi pool of RhoA. This is strange because the authors concede that GEF-H1 regulates RhoA in the entire cell, including the Golgi pool.\" If you can add a few words to make sure this is clarified, we will be delighted to publish your paper in eLife.

As requested by the reviewer, we have made changes to the manuscript text especially in the Results section to clarify that GEF-H1 promotes a general increase in cellular Rho activity and that active Rho in turn stimulates PKD activity at the TGN membranes.

For example, we corrected the sentence "Our data thus provide strong support for GEF-H1 promoting increased Rho activity at Golgi membranes." to "Our data thus provide strong support for GEF-H1 promoting increased Rho activity *in the cell periphery* and at the Golgi membranes."

We also corrected the sentence "Specifically, we demonstrated that GEF-H1, when released from microtubules, enhances RhoA activity at TGN membranes. Active RhoA in turn induces PKD activation through its effector PLCε ultimately leading to the fission of Rab6-positive vesicles that move towards FAs." to "Specifically, we demonstrate that GEF-H1, when released from microtubules, enhances cellular RhoA activity, which in turn promotes PKD activation at the TGN through the Rho effector PLCε, ultimately leading to the fission of Rab6-positive vesicles that move towards FAs."

In total, we changed the phrasing in nine sentences. With these changes the reader is no longer misled to assume that GEF-H1 specifically activates Rho at the Golgi complex.

[^1]: These authors contributed equally to this work.
